Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TELA Bio (TELA) EBITDA (2018 - 2025)

TELA Bio has reported EBITDA over the past 8 years, most recently at -$9.0 million for Q4 2025.

  • Quarterly results put EBITDA at -$9.0 million for Q4 2025, up 2.44% from a year ago — trailing twelve months through Dec 2025 was -$38.8 million (down 2.61% YoY), and the annual figure for FY2025 was -$38.8 million, down 2.61%.
  • EBITDA for Q4 2025 was -$9.0 million at TELA Bio, down from -$8.6 million in the prior quarter.
  • Over the last five years, EBITDA for TELA hit a ceiling of -$5.7 million in Q1 2024 and a floor of -$12.9 million in Q4 2023.
  • Median EBITDA over the past 5 years was -$9.7 million (2022), compared with a mean of -$9.6 million.
  • Biggest five-year swings in EBITDA: soared 53.1% in 2024 and later plummeted 99.17% in 2025.
  • TELA Bio's EBITDA stood at -$7.7 million in 2021, then dropped by 23.32% to -$9.4 million in 2022, then tumbled by 37.03% to -$12.9 million in 2023, then rose by 28.35% to -$9.3 million in 2024, then grew by 2.44% to -$9.0 million in 2025.
  • The last three reported values for EBITDA were -$9.0 million (Q4 2025), -$8.6 million (Q3 2025), and -$9.9 million (Q2 2025) per Business Quant data.